Market Place
Sourcing Support
Alvotech Initiates AVT16 Confirmatory Patient Study
25 Sep 2024 //
GLOBENEWSWIRE
PatientSeek Finds Genetic Signature For IBD Therapy Response
16 Sep 2024 //
GLOBENEWSWIRE
Spyre Therapeutics Doses First Participants In SPY001 Phase 1 Trial For IBD
18 Jun 2024 //
PR NEWSWIRE
FDA approves Takeda’s ENTYVIO SC for Crohn’s disease
20 Apr 2024 //
PHARMACEUTICAL-TECHNOLOGY
Takeda Pharms USA`s Entyvio (vedolizumab) Receives Suppl Approval In the US
19 Apr 2024 //
FDA
Takeda Pharma`s Biologic Entyvio (vedolizumab) Receives Approval in the U.S.
23 Feb 2024 //
FDA
Polpharma Biologics` biosimilar shows PK/PD comparability to blockbuster Entyvio
21 Feb 2024 //
PR NEWSWIRE
U.S. FDA Approves Subcutaneous Administration of Takeda`s ENTYVIO
27 Sep 2023 //
BUSINESSWIRE
Morphic`s stock sinks as data on oral Entyvio rival disappoint
25 Sep 2023 //
FIERCE BIOTECH
Takeda Announces FDA Acceptance of BLA for Administration of ENTYVIO
13 Sep 2023 //
BUSINESSWIRE
Takeda Announces FDA Acceptance of BLA Resubmission for Invgl Sub adm of Entyvio
27 Apr 2023 //
BUSINESSWIRE
Morphic shares swing on study data for drug viewed as ‘oral Entyvio’
26 Apr 2023 //
BIOPHARMADIVE
Takeda Announces Results From Phase 4 Vedolizumab Study
30 Mar 2023 //
BUSINESSWIRE
Takeda Receives Approval to Manufacture Entyvio Subcutaneous Injection in Japan
27 Mar 2023 //
PRESS RELEASE
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab
18 Feb 2023 //
BUSINESSWIRE
Japan`s Takeda to buy Nimbus` psoriasis drug for as much as $6 bln
14 Dec 2022 //
REUTERS
Not IDEAL: Protagonist sinks as oral Entyvio rival fails in IBD
26 Apr 2022 //
FIERCEBIOTECH
Takeda Receives Positive CHMP Opinion for Vedolizumab IV
17 Dec 2021 //
TAKEDA
Takeda Receives Positive CHMP Opinion for Vedolizumab IV
17 Dec 2021 //
BUSINESSWIRE
Crohn’s patients achieve 65 percent clinical remission with Tremfya
17 Nov 2021 //
EUROPEANPHARMACEUTICALREVIEW
Takeda Pharms Usa`s Biological Vedolizumab Receives Approval In the US
17 Aug 2021 //
FDA
Vedolizumab Improves Immunotherapy-Related Diarrhea, Colitis Better
28 Oct 2020 //
FIRSTWORLDPHARMA
Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During
12 Oct 2020 //
PRESS RELEASE
Takeda announces positive interim results from phase 3 VISIBLE OLE
12 Oct 2020 //
PHARMABIZ
Takeda launches vedolizumab to treat patients with colitis & Crohn`s disease
08 Jul 2020 //
PHARMABIZ
Takeda Receives U.S. FDA Approval to Manufacture ENTYVIO® (vedolizumab)
23 Jun 2020 //
PRESS RELEASE
Final NICE green light for Janssen`s Stelara in UC
17 Jun 2020 //
PHARMATIMES
Despite Increased Competition from the Recent Launch of Janssen`s Stelara
01 Jun 2020 //
PRNEWSWIRE
Takeda’s Entyvio SC Form Approved in Europe
11 May 2020 //
PHARMA-JAPAN
European Commission Approves Subcutaneous Formulation of Entyvio® (Vedolizumab)
08 May 2020 //
PRESS RELEASE
China approves Takeda’s treatment for ulcerative colitis and Crohn’s disease
23 Mar 2020 //
PHARMAFILE
Takeda: Subcutaneous Formulation Of Vedolizumab Receives Positive CHMP Opinion
28 Feb 2020 //
NASDAQ
Strong Ph 3 data for Takeda`s subcutaneous Entyvio in severe Crohn`s disease
18 Feb 2020 //
PHARMAFILE
Subcutaneous Entyvio hits Crohn’s primary endpoint, misses secondary
17 Feb 2020 //
PHARMA TIMES
Investigational Subcutaneous Formulation of Vedolizumab Achieves Remission
14 Feb 2020 //
AFM
Takeda`s subcutaneous Entyvio formulation faces FDA rejection
23 Dec 2019 //
PM LIVE
UPDATED: Zealand takes on Takeda`s IBD drug with tiny buyout
24 Oct 2019 //
ENDPTS
Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab
21 Oct 2019 //
BUSINESSWIRE
Entyvio beats Humira in head-to-head ulcerative colitis trial
27 Sep 2019 //
PHARMATIMES
Takeda reports further results from VARSITY ulcerative colitis study
27 Sep 2019 //
CLINICALTRIALSARENA
Subcutaneous Formulation of Takeda’s Entyvio Hits the Mark in Crohn’s Trial
23 Jul 2019 //
BIOSPACE
Takeda sets December deadline for U.S. employees` Boston move
27 Jun 2019 //
FIERCE PHARMA
Takeda scores Japanese Entyvio approval in Crohn`s disease
22 May 2019 //
PHARMAFILE
Takeda`s Entyvio beats Humira for remission in ulcerative colitis, data show
21 May 2019 //
PHARMAFILE
Phase 3b VARSITY study demonstrates superiority of vedolizumab to adalimumab
20 May 2019 //
PHARMABIZ
Velcade copy, Uloric patent loss will hurt post-Shire Takeda
15 May 2019 //
FIERCE PHARMA
U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application
09 May 2019 //
BUSINESSWIRE
Takeda Pharm USA Entyvio (Vedolizumab) Receives Supplemental Approval In US
09 May 2019 //
FDA
EMA accepts Takeda application for subcutaneous Entyvio
03 Apr 2019 //
PHARMA TIMES
FTC zeroes in on potential BMS, Celgene psoriasis overlap
27 Mar 2019 //
ENDPTS
Takeda’s Entyvio tops Humira in ulcerative colitis
12 Mar 2019 //
PMLIVE
Takeda hits FDA snag on Ninlaro, but its growth still helps drive revenue hike
01 Feb 2019 //
FIERCE PHARMA
Takeda eyes $3B from emerging-market asset cull
22 Jan 2019 //
FIERCE PHARMA
Takeda to win EU approval for $62 billion Shire deal - sources
10 Nov 2018 //
REUTERS
Takeda CEO confident of investor backing for $62 billion Shire deal
05 Nov 2018 //
REUTERS
Takeda ready to auction off a PhIII favorite at Shire to clear $62B buyout
30 Oct 2018 //
ENDPTS
Takeda`s $80 Billion Acquisition of Shire Hits Snag in Europe
29 Oct 2018 //
BIOSPACE
Stellar Phase III Data from Janssen`s Stelara
09 Oct 2018 //
BIOSPACE
